EP1924596A4 - Protéines de fusion avec l'albumine - Google Patents
Protéines de fusion avec l'albumineInfo
- Publication number
- EP1924596A4 EP1924596A4 EP06813242A EP06813242A EP1924596A4 EP 1924596 A4 EP1924596 A4 EP 1924596A4 EP 06813242 A EP06813242 A EP 06813242A EP 06813242 A EP06813242 A EP 06813242A EP 1924596 A4 EP1924596 A4 EP 1924596A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- fusion proteins
- albumin fusion
- albumin
- proteins
- fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70752105P | 2005-08-12 | 2005-08-12 | |
| US71238605P | 2005-08-31 | 2005-08-31 | |
| US73272405P | 2005-11-03 | 2005-11-03 | |
| US77691406P | 2006-02-28 | 2006-02-28 | |
| US78136106P | 2006-03-13 | 2006-03-13 | |
| US81018206P | 2006-06-02 | 2006-06-02 | |
| US81368206P | 2006-06-15 | 2006-06-15 | |
| PCT/US2006/029391 WO2007021494A2 (fr) | 2005-08-12 | 2006-07-31 | Proteines de fusion avec l'albumine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1924596A2 EP1924596A2 (fr) | 2008-05-28 |
| EP1924596A4 true EP1924596A4 (fr) | 2009-07-29 |
Family
ID=37758042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP06813242A Withdrawn EP1924596A4 (fr) | 2005-08-12 | 2006-07-31 | Protéines de fusion avec l'albumine |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1924596A4 (fr) |
| JP (1) | JP2009504157A (fr) |
| KR (1) | KR20080071119A (fr) |
| AU (1) | AU2006280312A1 (fr) |
| BR (1) | BRPI0614761A2 (fr) |
| CA (1) | CA2618476A1 (fr) |
| EC (1) | ECSP088262A (fr) |
| IL (1) | IL189246A0 (fr) |
| MA (1) | MA29836B1 (fr) |
| MX (1) | MX2008001865A (fr) |
| NO (1) | NO20081233L (fr) |
| TN (1) | TNSN08064A1 (fr) |
| WO (1) | WO2007021494A2 (fr) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| EP1803730A1 (fr) | 2000-04-12 | 2007-07-04 | Human Genome Sciences, Inc. | Proteines de fusion d'albumine |
| US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| EP1997829A1 (fr) | 2001-12-21 | 2008-12-03 | Human Genome Sciences, Inc. | Protéines de fusion d'albumine |
| HUE027902T2 (en) | 2004-02-09 | 2016-11-28 | Human Genome Sciences Inc Corp Service Company | Albumin fusion proteins |
| EP1816201A1 (fr) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée |
| EP2474318A1 (fr) | 2006-06-07 | 2012-07-11 | Human Genome Sciences, Inc. | Protéines de fusion d'albumine |
| KR20090064453A (ko) * | 2006-09-14 | 2009-06-18 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| CN107011431B (zh) | 2007-01-30 | 2020-11-06 | 埃皮瓦克斯公司 | 调节性t细胞表位、组合物及其用途 |
| WO2009150284A2 (fr) | 2008-06-13 | 2009-12-17 | Proyecto De Biomedicina Cima, S.L. | Conjugués pour l'administration de composés biologiquement actifs |
| US20100227818A1 (en) | 2009-01-16 | 2010-09-09 | Teva Biopharmaceuticals Usa, Inc. | Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor For The Prevention Of Neutropenia |
| JP5936112B2 (ja) | 2009-02-11 | 2016-06-15 | アルブミディクス アクティーゼルスカブ | アルブミン変異体及び複合体 |
| KR20100100254A (ko) * | 2009-03-05 | 2010-09-15 | (주)바이오큐어팜 | 인간 혈청 알부민-팀프-2 융합 단백질과 항암제를 포함하는암의 예방 또는 치료용 조성물 |
| JP2013502458A (ja) | 2009-08-24 | 2013-01-24 | アムニクス オペレーティング インコーポレイテッド | 凝固第ｖｉｉ因子組成物ならびにそれを製造および使用する方法 |
| BR112012009450A2 (pt) | 2009-10-30 | 2017-05-23 | Novozymes Biopharma Dk As | variantes de albumina |
| US10233228B2 (en) | 2010-04-09 | 2019-03-19 | Albumedix Ltd | Albumin derivatives and variants |
| US9238080B2 (en) * | 2010-05-21 | 2016-01-19 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins |
| EP3189835B1 (fr) * | 2011-02-28 | 2018-07-25 | National Cerebral and Cardiovascular Center | Agent médical de suppression de métastase de tumeurs malignes |
| CA2830660A1 (fr) | 2011-05-05 | 2012-11-08 | Novozymes Biopharma Dk A/S | Variants de l'albumine |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| HUE043894T2 (hu) | 2011-06-10 | 2019-09-30 | Bioverativ Therapeutics Inc | Koagulációt elõsegítõ vegyületek és alkalmazásuk módszerei |
| BR112014006314A2 (pt) | 2011-10-21 | 2017-04-11 | Abbvie Inc | métodos para tratamento do vírus da hepatite c (hcv) compreendendo pelo menos dois agentes antivirais de atuação direta, ribavirina, sem interferon |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| SG2014011670A (en) | 2011-10-21 | 2014-10-30 | Abbvie Inc | Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| HK1200842A1 (en) | 2011-11-18 | 2015-08-14 | Albumedix Ltd | Proteins with improved half-life and other properties |
| MX357403B (es) | 2012-01-12 | 2018-07-09 | Bioverativ Therapeutics Inc | Polipeptidos de factor viii quimericos y usos de los mismos. |
| BR112014020694A2 (pt) | 2012-02-15 | 2018-05-08 | Amunix Operating Inc. | proteína de fusão do fator viii compreendendo polipeptídeo do fator viii fusionado a polipeptí-deo recombinante estendido (xten) e seu método de fabricação, ácido nucleico, vetores, célula hospedeira, bem como composição farmacêutica e seu uso no tratamento de coagulopatia, episódio de hemorragia e hemofilia a |
| JP6383666B2 (ja) | 2012-02-15 | 2018-08-29 | バイオベラティブ セラピューティクス インコーポレイテッド | 組換え第ｖｉｉｉ因子タンパク質 |
| CN104736559B (zh) | 2012-03-16 | 2022-04-08 | 阿尔布梅迪克斯医疗有限公司 | 白蛋白变体 |
| WO2013185113A1 (fr) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Composés pro-coagulants |
| CN104427995A (zh) | 2012-06-08 | 2015-03-18 | 比奥根艾迪克Ma公司 | 嵌合凝血因子 |
| CN103525695B (zh) * | 2012-07-04 | 2015-05-20 | 长沙中生众捷生物技术有限公司 | 便携式肾功能检测系统 |
| EA201792485A3 (ru) | 2012-07-11 | 2019-03-29 | Амуникс Оперэйтинг Инк. | Комплекс фактора viii с xten и белком-фактором фон виллебранда, и его применение (варианты) |
| US10391152B2 (en) | 2012-10-18 | 2019-08-27 | Bioverativ Therapeutics Inc. | Methods of using a fixed dose of a clotting factor |
| CN105452290A (zh) | 2012-11-08 | 2016-03-30 | 诺维信生物制药丹麦公司 | 白蛋白变体 |
| US10370431B2 (en) | 2013-02-15 | 2019-08-06 | Bioverativ Therapeutics Inc. | Optimized factor VIII gene |
| CN105007722A (zh) | 2013-02-16 | 2015-10-28 | 诺维信生物制药丹麦公司 | 药代动力学动物模型 |
| AR095527A1 (es) | 2013-03-15 | 2015-10-21 | Biogen Idec Inc | Formulaciones de polipéptido fc-factor ix |
| US20160251408A1 (en) | 2013-06-28 | 2016-09-01 | Biogen Ma Inc. | Thrombin cleavable linker with xten and its uses thereof |
| WO2015023891A2 (fr) | 2013-08-14 | 2015-02-19 | Biogen Idec Ma Inc. | Fusions de facteur vii-xten et leurs utilisations |
| WO2015048330A2 (fr) | 2013-09-25 | 2015-04-02 | Biogen Idec Ma Inc. | Procédés d'inactivation de virus sur colonne |
| US10584147B2 (en) | 2013-11-08 | 2020-03-10 | Biovertiv Therapeutics Inc. | Procoagulant fusion compound |
| EP3091997B1 (fr) | 2014-01-10 | 2022-07-06 | Bioverativ Therapeutics Inc. | Protéines chimériques de facteur viii et leurs utilisations |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| EA201700181A1 (ru) | 2014-10-14 | 2017-09-29 | Галозим, Инк. | Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования |
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| EA201890423A1 (ru) | 2015-08-03 | 2018-07-31 | Биовератив Терапьютикс Инк. | Слитые белки фактора ix, способы их получения и применения |
| MX2018001825A (es) | 2015-08-20 | 2018-05-07 | Albumedix As | Variantes y conjugados de albumina. |
| EP3355907B1 (fr) | 2015-10-02 | 2021-01-20 | Silver Creek Pharmaceuticals, Inc. | Protéines thérapeutiques bispécifiques pour la réparation de tissus |
| CN105254766B (zh) * | 2015-10-26 | 2018-10-16 | 中国航天员科研训练中心 | 机械生长因子MGF E domain肽在调控记忆相关基因和miRNA表达中的应用 |
| EP3411478B1 (fr) | 2016-02-01 | 2022-06-08 | Bioverativ Therapeutics Inc. | Gènes du facteur viii optimisés |
| CN109689063B (zh) | 2016-04-28 | 2026-02-27 | 埃默里大学 | 含有炔烃的核苷酸和核苷治疗组合物及其相关用途 |
| US20210333279A1 (en) | 2016-11-04 | 2021-10-28 | Aarhus Universitet | Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor |
| KR20260008164A (ko) | 2016-12-02 | 2026-01-15 | 바이오버라티브 테라퓨틱스 인크. | 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법 |
| EP3548063A1 (fr) | 2016-12-02 | 2019-10-09 | Bioverativ Therapeutics Inc. | Procédés d'induction de tolérance immunitaire à des facteurs de coagulation |
| MA47163A (fr) | 2016-12-16 | 2019-11-06 | Biogen Ma Inc | Facteur 11 de différenciation de croissance activé protéolytiquement stabilisé |
| JP2020505424A (ja) | 2017-01-31 | 2020-02-20 | バイオベラティブ セラピューティクス インコーポレイテッド | 因子ｉｘ融合タンパク質ならびにその製造および使用方法 |
| MA50141A (fr) * | 2017-04-20 | 2020-07-29 | Novo Nordisk As | Procédés de purification de protéines de fusion d'albumine |
| JP7374883B2 (ja) | 2017-08-09 | 2023-11-07 | バイオベラティブ セラピューティクス インコーポレイテッド | 核酸分子およびその使用 |
| KR20200118089A (ko) | 2018-02-01 | 2020-10-14 | 바이오버라티브 테라퓨틱스 인크. | 인자 viii을 발현하는 렌티바이러스 벡터의 용도 |
| MA52630B1 (fr) | 2018-05-18 | 2025-07-31 | Bioverativ Therapeutics Inc. | Procédés de traitement de l'hémophilie a |
| MX2021000016A (es) | 2018-07-03 | 2021-03-09 | Bristol Myers Squibb Co | Formulaciones de factor de crecimiento de fibroblastos (fgf-21). |
| CA3108799A1 (fr) | 2018-08-09 | 2020-02-13 | Bioverativ Therapeutics Inc. | Molecules d'acide nucleique et leurs utilisations pour une therapie genique non virale |
| SG11202105880TA (en) | 2018-12-06 | 2021-07-29 | Bioverativ Therapeutics Inc | Use of lentiviral vectors expressing factor ix |
| JP7803014B2 (ja) | 2019-09-30 | 2026-01-21 | バイオベラティブ セラピューティクス インコーポレイテッド | レンチウイルスベクター製剤 |
| IL299333A (en) | 2020-06-24 | 2023-02-01 | Bioverativ Therapeutics Inc | Methods for the purification of viral vectors |
| WO2022030580A1 (fr) * | 2020-08-06 | 2022-02-10 | 国立大学法人宮崎大学 | Nouveau dérivé d'adrénomédulline à action prolongée, son procédé de production, et son utilisation pharmaceutique |
| US12487299B2 (en) | 2022-06-20 | 2025-12-02 | Shanghai United Imaging Healthcare Co., Ltd. | Magnetic resonance imaging devices and radiation therapy systems including the magnetic resonance imaging devices |
| JP2024056667A (ja) * | 2022-10-11 | 2024-04-23 | Ｊｃｒファーマ株式会社 | 血清アルブミンと生理活性を有する蛋白質との融合蛋白質 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003060071A2 (fr) * | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Proteines hybrides d'albumine |
| WO2005003296A2 (fr) * | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Proteines hybrides d'albumine |
| WO2005077042A2 (fr) * | 2004-02-09 | 2005-08-25 | Human Genome Sciences, Inc. | Proteines hybrides d'albumine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060051859A1 (en) * | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
-
2006
- 2006-07-31 EP EP06813242A patent/EP1924596A4/fr not_active Withdrawn
- 2006-07-31 CA CA002618476A patent/CA2618476A1/fr not_active Abandoned
- 2006-07-31 MX MX2008001865A patent/MX2008001865A/es not_active Application Discontinuation
- 2006-07-31 JP JP2008526056A patent/JP2009504157A/ja not_active Withdrawn
- 2006-07-31 KR KR1020087006077A patent/KR20080071119A/ko not_active Withdrawn
- 2006-07-31 BR BRPI0614761-5A patent/BRPI0614761A2/pt not_active IP Right Cessation
- 2006-07-31 AU AU2006280312A patent/AU2006280312A1/en not_active Abandoned
- 2006-07-31 WO PCT/US2006/029391 patent/WO2007021494A2/fr not_active Ceased
-
2008
- 2008-02-04 IL IL189246A patent/IL189246A0/en unknown
- 2008-02-11 TN TNP2008000064A patent/TNSN08064A1/en unknown
- 2008-03-07 MA MA30727A patent/MA29836B1/fr unknown
- 2008-03-10 NO NO20081233A patent/NO20081233L/no not_active Application Discontinuation
- 2008-03-12 EC EC2008008262A patent/ECSP088262A/es unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003060071A2 (fr) * | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Proteines hybrides d'albumine |
| WO2005003296A2 (fr) * | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Proteines hybrides d'albumine |
| WO2005077042A2 (fr) * | 2004-02-09 | 2005-08-25 | Human Genome Sciences, Inc. | Proteines hybrides d'albumine |
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP088262A (es) | 2008-05-30 |
| JP2009504157A (ja) | 2009-02-05 |
| KR20080071119A (ko) | 2008-08-01 |
| EP1924596A2 (fr) | 2008-05-28 |
| NO20081233L (no) | 2008-05-09 |
| AU2006280312A1 (en) | 2007-02-22 |
| MA29836B1 (fr) | 2008-10-03 |
| BRPI0614761A2 (pt) | 2009-05-19 |
| TNSN08064A1 (en) | 2009-07-14 |
| WO2007021494A2 (fr) | 2007-02-22 |
| MX2008001865A (es) | 2008-04-15 |
| IL189246A0 (en) | 2008-08-07 |
| CA2618476A1 (fr) | 2007-02-22 |
| WO2007021494A3 (fr) | 2007-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL189246A0 (en) | Albumin fusion proteins | |
| IL176894A0 (en) | Albumin fusion proteins | |
| IL222924A0 (en) | Albumin fusion proteins | |
| IL197580A0 (en) | Albumin fusion proteins | |
| PL1830872T3 (pl) | Białka fuzyjne | |
| GB0426397D0 (en) | Fusion proteins | |
| ZA200801224B (en) | Albumin fusion proteins | |
| IL204839A0 (en) | Albumin fusion proteins | |
| EP1858546A4 (fr) | Proteines hybrides modifiees de transferrine | |
| EP1594530A4 (fr) | Proteines hybrides d'albumine | |
| IL196889A0 (en) | Albumin-insulin fusion proteins | |
| ZA200709871B (en) | Interferon-IgG fusion | |
| EP1934372A4 (fr) | Proteines hybrides ssb-polymerase | |
| ZA200901280B (en) | Exendin fusion proteins | |
| GB0519965D0 (en) | Joint fusion peg | |
| GB0423974D0 (en) | Proteins | |
| PL1879909T3 (pl) | Roztwór albuminy pozbawiony cząsteczek stabilizatora | |
| HK1113581A (en) | Albumin fusion proteins | |
| GB0426399D0 (en) | Fusion proteins | |
| HK1131548A (en) | Albumin fusion proteins | |
| AU2005905300A0 (en) | Fusion Protein | |
| GB0511861D0 (en) | Proteins | |
| GB0423002D0 (en) | Proteins | |
| GB0513505D0 (en) | Proteins | |
| GB0514788D0 (en) | Proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20080312 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1113581 Country of ref document: HK |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20090626 |
|
| 17Q | First examination report despatched |
Effective date: 20100108 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20120201 |
|
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1113581 Country of ref document: HK |